Medifast stock gains as revenue reaches USD 76.38 million

Medifast stock (ISIN US58470S1024) traded at USD 11.73 on September 21, 2026, after gaining 20.5 percent since the company reported its latest quarterly results. The move followed revenue of USD 76.38 million for the reported quarter, although sales were 27.6 percent below the prior-year period.

Revenue remains the key test

According to Yahoo Finance on September 21, 2026, Medifast generated USD 76.38 million in quarterly revenue, down 27.6 percent year over year but 5.1 percent above analysts' expectations. That comparison gives the stock its clearest current tension: the absolute sales base is shrinking, while the result exceeded the consensus figure cited in the report.

The same September 2026 earnings review said Medifast also issued next-quarter EPS guidance above analysts' expectations. The source described the guidance as the highest raise among the companies covered in its comparison, while also identifying Medifast as the slowest revenue grower in that group.

Price reaction outpaced sales

The 20.5 percent share-price increase since the latest report is materially different from the 27.6 percent year-over-year revenue decline reported for the quarter. For investors, that gap makes forward earnings guidance more important than the headline sales trend, because the market response has rewarded the earnings outlook despite weaker top-line performance.

The quoted USD 11.73 price is a dated Nasdaq market figure for September 21, 2026. The available report also records the latest quarterly revenue, the year-over-year comparison and the 5.1 percent revenue surprise, providing three distinct reference points for assessing the stock's reaction.

Medifast stock stays tied to guidance

Medifast stock traded at USD 11.73 on Nasdaq on September 21, 2026. The next observable checkpoint is whether the above-expectation EPS guidance can offset the 27.6 percent revenue decline in the next reported period.

More news and analyses on Medifast stock